Spirox Liabilities 2024

Spirox Aktienanalyse

What does Spirox do?

The Spirox Corporation is a company that was founded in 2007 and is headquartered in Menlo Park, California. The company operates in the medical technology industry and specializes in the development of products for nasal breathing. The mission of Spirox is to help people who have difficulty breathing through their nose. The company has recognized that many people have difficulty breathing through their nose due to congestion or other issues. Breathing through the mouth, however, can lead to a range of health problems such as dry mouth, sleep apnea, and respiratory infections. Therefore, Spirox has set out to develop innovative solutions to facilitate nasal breathing. Spirox's products include both implantable and non-implantable solutions. The company has a small but effective product portfolio consisting of two products: the Latera Nasal Stent and the AeroForm Nasal Stent. The Latera Nasal Stent is used to permanently open the nasal passages and facilitate breathing. The placement of the stent is a minimally invasive procedure that is typically performed on an outpatient basis. The Latera Nasal Stent is inserted and secured in the nasal wings to allow for better airflow through the nostrils. The stent is made of polydioxanone (PDO), a biocompatible polymer fiber that is absorbed by the body. Spirox's second product, the AeroForm Nasal Stent, is a non-implantable nasal stent used for temporary relief of nasal breathing. The AeroForm is a soft stent made of a flexible polymer material. It is inserted into the nasal passages and forms a gentle expansion to facilitate nasal breathing. As a company, Spirox focuses on collaboration with specialists and clinics to ensure that their products have high success rates. The company has established a partnership with the American Academy of Otolaryngology - Head and Neck Surgery (AAO-HNS) to advance scientific research and development in the nasal breathing industry. Spirox is led by experienced executives from the medical technology industry. The CEO, Duke Rohlen, has over 20 years of experience in leading medical technology companies such as Inspire Medical Systems and CV Ingenuity. The board team also includes Elektra Papadopoulos as Chair of the Board, who has worked at Hologic and Boston Scientific, among others. Although Spirox is a relatively small company, it has already received several awards. In 2017, the company was awarded the Red Herring Top 100 North America Award, which recognizes companies that are leading in the innovation industry. Overall, Spirox is an emerging company in the medical technology industry that offers innovative solutions to facilitate nasal breathing. Through collaboration with doctors and clinics and a focus on scientific research, the company aims to improve the success and effectiveness of its products. Spirox ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Spirox's Liabilities

Spirox's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Spirox's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Spirox's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Spirox's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Spirox’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Spirox stock

What is the level of liabilities of Spirox this year?

Spirox has a debt balance of 1.11 B TWD this year.

What were the liabilities of Spirox compared to the previous year?

The liabilities of Spirox have increased by -12.75% dropped compared to the previous year.

What are the consequences of high debt for investors of Spirox?

High liabilities can pose a risk for investors of Spirox, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Spirox?

Low liabilities mean that Spirox has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Spirox affect the company?

An increase in liabilities of Spirox can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Spirox affect the company?

A decrease in the liabilities of Spirox can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Spirox?

Some factors that can influence the liabilities of Spirox include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Spirox so important for investors?

The liabilities of Spirox are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Spirox take to modify the liabilities?

To change its liabilities, Spirox can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Spirox pay?

Over the past 12 months, Spirox paid a dividend of 1 TWD . This corresponds to a dividend yield of about 1.48 %. For the coming 12 months, Spirox is expected to pay a dividend of 0.87 TWD.

What is the dividend yield of Spirox?

The current dividend yield of Spirox is 1.48 %.

When does Spirox pay dividends?

Spirox pays a quarterly dividend. This is distributed in the months of October, August, August, August.

How secure is the dividend of Spirox?

Spirox paid dividends every year for the past 0 years.

What is the dividend of Spirox?

For the upcoming 12 months, dividends amounting to 0.87 TWD are expected. This corresponds to a dividend yield of 1.29 %.

In which sector is Spirox located?

Spirox is assigned to the 'Information technology' sector.

Wann musste ich die Aktien von Spirox kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Spirox from 8/6/2024 amounting to 1.011 TWD, you needed to have the stock in your portfolio before the ex-date on 7/5/2024.

When did Spirox pay the last dividend?

The last dividend was paid out on 8/6/2024.

What was the dividend of Spirox in the year 2023?

In the year 2023, Spirox distributed 0.2 TWD as dividends.

In which currency does Spirox pay out the dividend?

The dividends of Spirox are distributed in TWD.